NewAmsterdam Market Capitalization from 2010 to 2024

NAMS Stock   19.85  0.95  4.57%   
NewAmsterdam Pharma Market Cap yearly trend continues to be comparatively stable with very little volatility. Market Cap is likely to outpace its year average in 2024.
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Market Capitalization Growth Pattern

Below is the plot of the Market Cap of NewAmsterdam Pharma over the last few years. It is NewAmsterdam Pharma's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 2.29 B10 Years Trend
Slightly volatile
   Market Cap   
       Timeline  

NewAmsterdam Market Capitalization Regression Statistics

Arithmetic Mean249,514,392
Geometric Mean196,318,624
Coefficient Of Variation98.01
Mean Deviation160,402,694
Median154,127,289
Standard Deviation244,545,151
Sample Variance59802.3T
Range719.6M
R-Value0.61
Mean Square Error40807.8T
R-Squared0.37
Significance0.02
Slope33,097,888
Total Sum of Squares837232.6T

NewAmsterdam Market Capitalization History

2024871.8 M
2023830.3 M
2022193.1 M
2021152.2 M

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
NewAmsterdam Pharma is entity of United States. It is traded as Stock on NASDAQ exchange.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.